The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.

Viljoen A, Chubb B, Malkin SJP, Berry S, Hunt B, Bain SC

The European journal of health economics : HEPAC : health economics in prevention and care17 Sept 2022Cited by 4 (Europe PMC)

PMID36114904PMCIDPMC10290607DOI10.1007/s10198-022-01514-1PepBankPUB-36114904

Download PDF PubMedAsk about this study

Jump to 14 results

Summary

AimsOnce-weekly semaglutide and dulaglutide represent two highly efficacious treatment options for type 2 diabetes. A recent indirect treatment comparison (ITC) has associated semaglutide 1 mg with similar and greater improvements in glycated haemoglobin (HbA1c) and body weight, respectively, vs. dulaglutide 3 mg and 4.5 mg. The present study aimed to evaluate the long-term cost-effectiveness of semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.Materials and methodsThe IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes. Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC. Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin. Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.ResultsSemaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide. Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively. Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.ConclusionsSemaglutide 1 mg represents a cost-effective treatment vs. dulaglutide 3 mg and 4.5 mg for type 2 diabetes from a healthcare payer perspective in the UK.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide 1 mg increased quality-adjusted life expectancy by 0.05 QALYs versus dulaglutide 3 mg.
In plain wordsIn computer models, semaglutide increased quality-adjusted life expectancy compared with dulaglutide 3 mg.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy versus dulaglutide 3 mg
Study
n: not reported in source
Comparator
Dulaglutide 3 mg
Outcome group
Quality of life · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490401
02Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide 1 mg increased quality-adjusted life expectancy by 0.04 QALYs versus dulaglutide 4.5 mg.
In plain wordsIn computer models, semaglutide increased quality-adjusted life expectancy compared with dulaglutide 4.5 mg.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy versus dulaglutide 4.5 mg
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg
Outcome group
Quality of life · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490402
03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide 3 mg yielded 0.05 fewer QALYs than semaglutide 1 mg.
In plain wordsIn computer models, dulaglutide 3 mg yielded lower quality-adjusted life expectancy than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQuality-adjusted life expectancy with dulaglutide 3 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Quality of life · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490403
04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide 4.5 mg yielded 0.04 fewer QALYs than semaglutide 1 mg.
In plain wordsIn computer models, dulaglutide 4.5 mg yielded lower quality-adjusted life expectancy than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQuality-adjusted life expectancy with dulaglutide 4.5 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Quality of life · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490404
05Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide direct costs were GBP 76 lower than dulaglutide 3 mg.
In plain wordsIn computer models, semaglutide cost less than dulaglutide 3 mg.
Peptide
Semaglutide
Outcome
DecreaseDirect costs versus dulaglutide 3 mg
Study
n: not reported in source
Comparator
Dulaglutide 3 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490405
06Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide direct costs were GBP 8 higher than dulaglutide 4.5 mg.
In plain wordsIn computer models, semaglutide cost more than dulaglutide 4.5 mg.
Peptide
Semaglutide
Outcome
IncreaseDirect costs versus dulaglutide 4.5 mg
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490406
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide 3 mg direct costs were GBP 76 higher than semaglutide.
In plain wordsIn computer models, dulaglutide 3 mg cost more than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDirect costs with dulaglutide 3 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490407
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide 4.5 mg direct costs were GBP 8 lower than semaglutide.
In plain wordsIn computer models, dulaglutide 4.5 mg cost less than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDirect costs with dulaglutide 4.5 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490408
09Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide reduced diabetes-related complications compared with dulaglutide.
In plain wordsIn computer models, semaglutide produced fewer diabetes complications than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseDiabetes-related complications
Study
n: not reported in source
Comparator
Dulaglutide 3 mg and 4.5 mg
Outcome group
Adverse events · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490409
10Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide produced more diabetes-related complications than semaglutide.
In plain wordsIn computer models, dulaglutide produced more diabetes complications than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDiabetes-related complications
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Adverse events · Whole body
Source sentences
Summary
Semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490410
11Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide was economically dominant versus dulaglutide 3 mg.
In plain wordsIn computer models, semaglutide was economically dominant compared with dulaglutide 3 mg.
Peptide
Semaglutide
Outcome
Not applicableEconomic dominance versus dulaglutide 3 mg
Study
n: not reported in source
Comparator
Dulaglutide 3 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490411
12Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, dulaglutide 3 mg was economically dominated by semaglutide.
In plain wordsIn computer models, dulaglutide 3 mg was economically dominated by semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableEconomic dominance with dulaglutide 3 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490412
13Computer modelNot a test of Semaglutide aloneIn silicoOther
In a UK diabetes model, semaglutide had an incremental cost-effectiveness ratio of GBP 228 per QALY versus dulaglutide 4.5 mg.
In plain wordsIn computer models, semaglutide cost GBP 228 per extra quality-adjusted life year compared with dulaglutide 4.5 mg.
Peptide
Semaglutide
Outcome
Not applicableIncremental cost-effectiveness versus dulaglutide 4.5 mg
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3611490413
14Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a UK diabetes model, semaglutide versus dulaglutide 4.5 mg had an incremental cost-effectiveness ratio of GBP 228 per QALY.
In plain wordsIn computer models, semaglutide cost GBP 228 per extra quality-adjusted life year compared with dulaglutide 4.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIncremental cost-effectiveness comparison with semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients' lifetimes.
Summary · context
Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC.
Summary · context
Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
Summary · context
Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3611490414

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.

Summary

Results from this study14

Studies that did not test the peptide alone14

Version history

Subjects

Publication types

MeSH terms

Keywords